RxDoctor Payments Data

Lindsay Anderson, MD

Internal Medicine · Noblesville, INNPI 1831489756

Payments from drug & device makers

$1,316in general payments, 2019–2025

Across 93 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • GSK$167
  • Lilly USA, LLC$150
  • AbbVie$143
  • Dexcom, Inc.$75
  • Amgen$60
  • plus $523 from 21 others

What the payments were for

  • Food & beverage$1,30499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,316 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$160,241
Medicare patients
423
Services billed
2,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$91,998
OzempicSemaglutide54$85,878
EliquisApixaban65$77,109
TrulicityDulaglutide49$68,457
MounjaroTirzepatide46$48,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,465
Breo ElliptaFluticasone/Vilanterol31$17,930
XareltoRivaroxaban15$16,396
FarxigaDapagliflozin Propanediol11$12,174
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,375
Potassium Chloride125$5,242
Atorvastatin Calcium534$4,484
SynthroidLevothyroxine Sodium79$3,711
SymbicortBudesonide/Formoterol Fumarate11$3,618
Omeprazole255$3,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$150$116,53095 claims
Novo NordiskOzempic$197$85,87854 claims
PfizerEliquis$35$77,10965 claims
GSKTrelegy Ellipta, Breo Ellipta$167$36,39551 claims
AstraZenecaFarxiga, Symbicort$49$15,79322 claims
AbbVieSynthroid$143$3,71179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →